A confirmatory measurement should always be undertaken in the case of a primary pathological value, and before starting any testosterone therapy. Considering that suppression of HPG axis activity is functional and potentially reversible by empiric measures, such as weight loss, the need for testosterone therapy has been questioned . The European Male Aging Study (EMAS) reported a 0.4% per annum (log hormone-age) decrease in total testosterone and a 1.3% per annum decline in free testosterone (fT) . A cohort study, analysing two large academic health systems databases, including 723 men with a history of COVID-19, reported that men with hypogonadism had a higher risk of being hospitalised .
In non-human primates, it may be that testosterone in puberty stimulates sexual arousal, which allows the primate to increasingly seek out sexual experiences with females and thus creates a sexual preference for females. Every mammalian species examined demonstrated a marked increase in a male's testosterone level upon encountering a novel female. In women, correlations may exist between positive orgasm experience and testosterone levels. Common side effects from testosterone medication include acne, swelling, and breast enlargement in males. Testosterone is used as a medication for the treatment of male hypogonadism, gender dysphoria, and certain types of breast cancer. In androgen-deficient men with concomitant autoimmune thyroiditis, substitution therapy with testosterone leads to a decrease in thyroid autoantibody titres and an increase in thyroid's secretory capacity (SPINA-GT). Testosterone does not appear to increase the risk of developing prostate cancer.
As support of the aforementioned considerations, a meta-analysis including 2,043 patients older than 60 years failed to show a significant improvement in muscle strength from testosterone therapy when compared to placebo . Similarly, there is a lack of evidence regarding the combined use of testosterone therapy with other pharmacological treatments for ED 3,96. Testosterone is involved in the regulation of erythropoiesis and prostate growth , hence evaluation of PSA and haematocrit should be mandatory before and during testosterone therapy. Patients at high risk of developing elevated haematocrit should be evaluated every three months during the first year of testosterone therapy and at least every six months thereafter. Additional risk factors for increased haematocrit during therapy include smoking and pre-existing respiratory conditions.
Whether you're deep in a fertility journey, investigating unexplained symptoms, or simply reviewing routine bloodwork, an elevated LH level demands attention. Digital rectal examination may detect prostate abnormalities that can be present even in men with normal PSA values. Baseline and, at least, annually glyco-metabolic profile evaluation may be a reasonable consideration, particularly in the management of functional hypogonadism. Testosterone Trials were designed to maintain the serum testosterone concentration within the normal range for young men ( ng/dL or 9.6-30nmol/L) . In cases of elevated haematocrit without comorbidities, acute CV or venous thromboembolism events, management can include reducing the testosterone dose, switching to a different formulation, or - if haematocrit is markedly high - performing venesection (500mL), repeated if necessary. Testosterone therapy is contraindicated in men with severe chronic cardiac failure because fluid retention may lead to exacerbation of the condition.
Some of these effects may decline as testosterone levels might decrease in the later decades of adult life. In males, these are usual late pubertal effects, and occur in women after prolonged periods of heightened levels of free testosterone in the blood. For postnatal effects in both males and females, these are mostly dependent on the levels and duration of circulating free testosterone. The biochemical diagnosis of hypogonadism should be made carefully, as there are significant intra-individual fluctuations in testosterone levels49 and no accepted cut-off that defines "low testosterone". More recent evidence from placebo-controlled studies of hypogonadal men receiving androgen therapy, indicate that the differences between those men receiving testosterone and those on placebo were insignificant in regards to prostate volume, PSA and BOO.24 There seems to be little doubt that the treatment with testosterone of a young hypogonadal male leads to significant growth of the prostate. Indeed, in eugonadal men, studies have demonstrated that the prostate can increase in volume by approximately 12%16 with the addition of testosterone, which is thought may be enough to decompensate a significantly obstructed bladder.

Gender: Female

Social links